TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19801235

Group type: EXPERIMENTAL
Intervention: Carbamide peroxide (30%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide (35%)
Number of subjects: 0
Study: 16717335

Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine (15-mL bolus, starting concentration 0.425%)
Number of subjects: 2
Study: 14699020

Group type: EXPERIMENTAL
Intervention: Folic acid (0.8 mg), vitamin B12 (0.4 mg), and vitamin B6 (40 mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Folic acid (0.8 mg) and vitamin B12 (0.4 mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Vitamin B6 alone (40 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups after 3 months of intervention
Number of subjects: 90
Study: 11704086

Group type: EXPERIMENTAL
Intervention: 23-day regimen
Number of subjects: 703

Group type: COMPARATOR
Intervention: 21-day regimen
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 703
Study: 8976239

Group type: EXPERIMENTAL
Intervention: Vibratory stimulation
Number of subjects: 77

Group type: COMPARATOR
Intervention: Electroejaculation
Number of subjects: 77
Study: 8823220

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 2218871

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus cyclophosphamide, methotrexate, and 5-fluorouracil
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 311

Group type: COMPARATOR
Intervention: Bacillus Calmette-Guerin plus cyclophosphamide, methotrexate, 5-fluorouracil, and tamoxifen
Number of subjects: 311
Study: 6157258

Group type: EXPERIMENTAL
Intervention: Mestranol (80 microgram/d) and chlormadinonacetate
Number of subjects: 12
Study: 31209595

Group type: COMPARATOR
Intervention: Any anticoagulant use
Number of subjects: 75336

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 75336

Group type: COMPARATOR
Intervention: Low-molecular-weight heparins (LMWH)
Number of subjects: 75336

Group type: EXPERIMENTAL
Intervention: Anticoagulant non-users
Number of subjects: 75336
Study: 28358236

Group type: EXPERIMENTAL
Intervention: Better distress tolerance
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Lower experiential avoidance
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Experiential avoidance (when both predictors examined simultaneously)
Number of subjects: 117
Study: 25964404

Group type: EXPERIMENTAL
Intervention: Weekend-only recreational drug use
Number of subjects: 483
Study: 24888316

Group type: EXPERIMENTAL
Intervention: Myrtle fruit syrup (15 ml daily for 7 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22696989

Group type: EXPERIMENTAL
Intervention: Gamma 3 nail
Number of subjects: 112

Group type: COMPARATOR
Intervention: ACE trochanteric nail
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both implants
Number of subjects: 112
Study: 19404189

Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham needling
Number of subjects: 35
Study: 17571966

Group type: EXPERIMENTAL
Intervention: Wheat grass juice (WGJ) 60 cc orally daily during the first three cycles of chemotherapy
Number of subjects: 60
Study: 15965796

Group type: EXPERIMENTAL
Intervention: Out-patients
Number of subjects: 129681

Group type: COMPARATOR
Intervention: Patients from nursing care units
Number of subjects: 129681
Study: 11836778

Group type: EXPERIMENTAL
Intervention: Segmentation method combining expectation‐maximization (EM) tissue segmentation, template‐driven segmentation (TDS), and partial volume effect correction (PVEC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Radiologist outlines of WMSA
Number of subjects: 30
Study: 10404794

Group type: EXPERIMENTAL
Intervention: Hyperthyroidism
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Restoration of euthyroidism
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Propranolol treatment
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Severe hyperthyroidism
Number of subjects: 42
Study: 8790827

Group type: EXPERIMENTAL
Intervention: New formulation of flunisolide nasal spray
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Original formulation of flunisolide nasal spray
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 216
Study: 1617763

Group type: EXPERIMENTAL
Intervention: 100 mg alteplase (rt-PA)
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: Immediate PTCA
Number of subjects: 1088

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: Alteplase, heparin, and aspirin
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: Routine immediate PTCA
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: Coronary anatomy, left ventricular function, age, and previous infarction
Number of subjects: 1088
Study: 6147213

Group type: EXPERIMENTAL
Intervention: Synthetic CRF-41 100 micrograms
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control infusion
Number of subjects: 6
Study: 31003961

Group type: COMPARATOR
Intervention: Balloon dilation for 0 seconds
Number of subjects: 1920

Group type: EXPERIMENTAL
Intervention: Balloon dilation for 30 seconds
Number of subjects: 1920

Group type: EXPERIMENTAL
Intervention: Balloon dilation for 60 seconds
Number of subjects: 1920

Group type: EXPERIMENTAL
Intervention: Balloon dilation for 180 seconds
Number of subjects: 1920

Group type: EXPERIMENTAL
Intervention: Balloon dilation for 300 seconds
Number of subjects: 1920

Group type: EXPERIMENTAL
Intervention: Overall outcomes
Number of subjects: 1920
Study: 29496259

Group type: EXPERIMENTAL
Intervention: Knotless barbed suture
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conventional suture
Number of subjects: 102
Study: 26028346

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 1347

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 1347

Group type: EXPERIMENTAL
Intervention: Combined treatment (Ranibizumab and Bevacizumab)
Number of subjects: 1347
Study: 23842831

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Supervised exercise programme (SEP)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Combined treatment (PTA + SEP)
Number of subjects: 178
Study: 21436463

Group type: EXPERIMENTAL
Intervention: High-altitude exposure (5,400 m) for 2 weeks
Number of subjects: 33
Study: 19103434

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (2400 mg daily) for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine self-administration or osmotic minipumps
Number of subjects: 0
Study: 17763261

Group type: EXPERIMENTAL
Intervention: 1EV/2DNG
Number of subjects: 98

Group type: COMPARATOR
Intervention: E2/NETA
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 1EV/2DNG/E2/NETA
Number of subjects: 98
Study: 15270927

Group type: EXPERIMENTAL
Intervention: Early postnatal discharge combined with home midwifery support (n=228)
Number of subjects: 459

Group type: COMPARATOR
Intervention: Traditional postnatal hospital stay (n=231)
Number of subjects: 459
Study: 11442521

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 5456
Study: 7951614

Group type: EXPERIMENTAL
Intervention: Triptoreline (Décapeptyl* 3.75 mg)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Gosereline (Zoladex*)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Leuproreline (Enantone* 3.75 mg)
Number of subjects: 198
Study: 3519227

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control
Number of subjects: 52
Study: 31757648

Group type: EXPERIMENTAL
Intervention: Positive anti-phospholipid antibodies (aPLs)
Number of subjects: 1712

Group type: EXPERIMENTAL
Intervention: aGPI IgA
Number of subjects: 1712

Group type: EXPERIMENTAL
Intervention: Positive history of cardiovascular events
Number of subjects: 1712

Group type: EXPERIMENTAL
Intervention: Peripheral obliterans arterial vasculopathy
Number of subjects: 1712

Group type: EXPERIMENTAL
Intervention: aPL positivity among high CV risk subjects (Framingham risk score >20, diabetes, BMI >35 kg/m2)
Number of subjects: 1712
Study: 29782435

Group type: EXPERIMENTAL
Intervention: Swaddled tub bath
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional tub bath
Number of subjects: 43
Study: 27323753

Group type: EXPERIMENTAL
Intervention: Chemoradiation (CRT)
Number of subjects: 608

Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 608
Study: 24825371

Group type: EXPERIMENTAL
Intervention: Weak patients
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Weak patients with persistent weakness
Number of subjects: 227
Study: 23783292

Group type: EXPERIMENTAL
Intervention: Vitamin D-fortified milk and bread
Number of subjects: 782

Group type: COMPARATOR
Intervention: Nonfortified milk and bread (Control)
Number of subjects: 782
Study: 20598488

Group type: EXPERIMENTAL
Intervention: Fetal Alcohol Syndrome (FAS)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Children with PEA
Number of subjects: 51

Group type: COMPARATOR
Intervention: Non-alcohol-exposed children (NC)
Number of subjects: 51
Study: 17681110

Group type: EXPERIMENTAL
Intervention: Heat pain stimuli
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ischaemic pain stimuli
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Delayed-onset muscle pain stimuli
Number of subjects: 44
Study: 16386942

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation, 1000 microg/day during 1 week (n=30)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Folic acid (800 microg/day), B12 (20 microg/day), and B6 (4 mg/day) during 1 week (n=29)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 14691345

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Rabeprazole 20 mg
Number of subjects: 32
Study: 10771231

Group type: EXPERIMENTAL
Intervention: CeeOn model 911F (sharp optic edges)
Number of subjects: 50

Group type: COMPARATOR
Intervention: CeeOn model 920 (rounded optic edges)
Number of subjects: 50
Study: 8610709

Group type: EXPERIMENTAL
Intervention: Food frequency questionnaire
Number of subjects: 203

Group type: COMPARATOR
Intervention: Interviewer-administered diet history
Number of subjects: 203
Study: 1731544

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 75

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 75
Study: 3530769

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg X 3 daily
Number of subjects: 2279
Study: 28716693

Group type: EXPERIMENTAL
Intervention: Neurodevelopmental therapy combined with reflexology
Number of subjects: 40

Group type: COMPARATOR
Intervention: Neurodevelopmental therapy alone
Number of subjects: 40
Study: 25737426

Group type: EXPERIMENTAL
Intervention: Aerobic walking
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Non-aerobic flexibility, toning, and balance
Number of subjects: 179

Group type: COMPARATOR
Intervention: Both groups (aerobic walking and non-aerobic flexibility)
Number of subjects: 179
Study: 25002241

Group type: EXPERIMENTAL
Intervention: 3D laparoscopy
Number of subjects: 56

Group type: COMPARATOR
Intervention: 2D laparoscopy
Number of subjects: 56
Study: 22474202

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 with cetuximab
Number of subjects: 2686

Group type: COMPARATOR
Intervention: mFOLFOX6 alone
Number of subjects: 2686
Study: 21784327

Group type: EXPERIMENTAL
Intervention: Plumbum metallicum 15 cH, orally for 35 days
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo, orally for 35 days
Number of subjects: 131
Study: 18926844

Group type: EXPERIMENTAL
Intervention: Tilt Illusion (TI) with briefly flashed context
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tilt Illusion (TI) with simultaneous context and inducer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rod and Frame Illusion (RFI) with visible frame for at least 800 ms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measures of illusion magnitude and discriminability
Number of subjects: 0
Study: 16308341

Group type: EXPERIMENTAL
Intervention: Adalimumab plus methotrexate (MTX)
Number of subjects: 271
Study: 15623951

Group type: EXPERIMENTAL
Intervention: Fluconazole 100 mg once weekly for 12 months with topical ketoconazole cream
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Fluconazole 150 mg once weekly for 12 months with topical ketoconazole cream
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Fluconazole 300 mg once weekly for 12 months with topical ketoconazole cream
Number of subjects: 121
Study: 11273142

Group type: EXPERIMENTAL
Intervention: Losartan potassium 50 mg
Number of subjects: 145

Group type: COMPARATOR
Intervention: Enalapril maleate 5 mg
Number of subjects: 145
Study: 9377073

Group type: EXPERIMENTAL
Intervention: Busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg) (CY) in study I
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY) + TBI (200 mg/kg) + antithymocyte globulin (ATG) in study II
Number of subjects: 19

Group type: COMPARATOR
Intervention: Not applicable (control group from study I)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Not applicable (comparison between unrelated donor marrow and HLA-matched sibling donors)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Not applicable (comparison of engraftment rates)
Number of subjects: 19
Study: 8259754

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol therapy (Estraderm 50 micrograms/24h)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study: 3853581

Group type: EXPERIMENTAL
Intervention: Mevinolin 10 mg BID
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mevinolin 20 mg BID
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mevinolin (both doses)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 28856592

Group type: EXPERIMENTAL
Intervention: Dental health education and ultrasonic baths for denture cleaning (n=144)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Control group (n=75)
Number of subjects: 219
Study: 26790579

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study: 25314063

Group type: EXPERIMENTAL
Intervention: Adjuvant gemcitabine treatment
Number of subjects: 162

Group type: COMPARATOR
Intervention: No adjuvant treatment (observation)
Number of subjects: 162
Study: 22366894

Group type: EXPERIMENTAL
Intervention: Continuous passive motion at 15º/s for 20 min
Number of subjects: 16

Group type: COMPARATOR
Intervention: Continuous passive motion at 0º/s for 20 min (control)
Number of subjects: 16
Study: 19730448

Group type: EXPERIMENTAL
Intervention: Posterior continuous curvilinear capsulorhexis (PCCC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (fellow eye without PCCC)
Number of subjects: 20
Study: 18388088

Group type: COMPARATOR
Intervention: Amlodipine 5 mg/d increasing to 10 mg
Number of subjects: 86

Group type: COMPARATOR
Intervention: Eprosartan 600 mg/d increasing to 600 mg twice a day
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg/d and indapamide 2.5 mg/d, increasing amlodipine to 10 mg/d
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Imidapril 10 mg/d and indapamide 2.5 mg/d, imidapril doubled to 20 mg/d
Number of subjects: 86
Study: 16018157

Group type: EXPERIMENTAL
Intervention: Specific inspiratory muscle training (SIMT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 20
Study: 12453815

Group type: EXPERIMENTAL
Intervention: Community-based program to prevent drug use initiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control area (no intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention activities in schools
Number of subjects: 0
Study: 10901689

Group type: EXPERIMENTAL
Intervention: Diary and Self-Instructional Training (DSIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diary Only (DO)
Number of subjects: 0
Study: 7492156

Group type: EXPERIMENTAL
Intervention: Casein hydrolysate formula (n = 24)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Whey hydrolysate formula (n = 21)
Number of subjects: 45
Study: 1789815

Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg q.p.m. for group I, 40 mg q.p.m. for group II)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Gemfibrozil (600 mg b.i.d.)
Number of subjects: 182
Study: 6216621

Group type: EXPERIMENTAL
Intervention: Woven Dacron grafts (USCI, DeBakey, C. R. Bard, Inc.)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Knitted Dacron grafts (Microvel, Meadox Medicals, Inc.)
Number of subjects: 24
Study: 31066510

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy (RP)
Number of subjects: 0
Study: 28821950

Group type: EXPERIMENTAL
Intervention: ECC110
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: ECC80
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study: 26026121

Group type: COMPARATOR
Intervention: Weekly docetaxel (36 mg/m2, days 1 and 8)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Weekly docetaxel (36 mg/m2, days 1 and 8) plus oxaliplatin (80 mg/m2, day 1)
Number of subjects: 52
Study: 24814697

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 34
Study: 21081539

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention with diabetes educator every 4-6 weeks and pedometer use
Number of subjects: 1650

Group type: EXPERIMENTAL
Intervention: Pedometer use
Number of subjects: 1650

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1650
Study: 19750572

Group type: EXPERIMENTAL
Intervention: H pylori eradication therapy
Number of subjects: 4133

Group type: COMPARATOR
Intervention: Conventional antacid therapy (non-eradication group)
Number of subjects: 4133

Group type: EXPERIMENTAL
Intervention: Successful eradication therapy
Number of subjects: 4133

Group type: EXPERIMENTAL
Intervention: Treatment failure
Number of subjects: 4133
Study: 16356598

Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate (PCV7) vaccine administered concurrently with DTaP.IPV/Hib and hepatitis B vaccines
Number of subjects: 368

Group type: COMPARATOR
Intervention: 7-valent pneumococcal conjugate (PCV7) vaccine administered sequentially with DTaP.IPV/Hib and hepatitis B vaccines
Number of subjects: 368
Study: 15051188

Group type: EXPERIMENTAL
Intervention: 35% CO2 inhalation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Patients with eating disorder (ED)
Number of subjects: 42
Study: 11772282

Group type: EXPERIMENTAL
Intervention: Trimegestone 0.5 mg/day
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Trimegestone 0.25 mg/day
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Trimegestone 0.1 mg/day
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Trimegestone 0.05 mg/day
Number of subjects: 96

Group type: COMPARATOR
Intervention: Norethisterone acetate
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Trimegestone (all doses)
Number of subjects: 96
Study: 9256568

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch (TNP; 21 mg)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Video-enhanced self-help treatment manual
Number of subjects: 424

Group type: COMPARATOR
Intervention: Self-help treatment manual only
Number of subjects: 424
Study: 8209057

Group type: EXPERIMENTAL
Intervention: 5 mg nebulized salbutamol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3304324

Group type: EXPERIMENTAL
Intervention: Silicon Polymer Foam dressing
Number of subjects: 40

Group type: COMPARATOR
Intervention: Other non-adherent dressings
Number of subjects: 40
Study: 30088679

Group type: EXPERIMENTAL
Intervention: Single-incision mini-sling (SIMS)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Transobturator sling (TOT)
Number of subjects: 130
Study: 28284575

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus panitumumab
Number of subjects: 100

Group type: COMPARATOR
Intervention: 5-FU/LV plus panitumumab
Number of subjects: 100
Study: 26221815

Group type: EXPERIMENTAL
Intervention: Interventions performed by teachers
Number of subjects: 1316

Group type: EXPERIMENTAL
Intervention: Interventions performed by experts
Number of subjects: 1316

Group type: EXPERIMENTAL
Intervention: Single lecture interventions
Number of subjects: 1316

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1316
Study: 23789714

Group type: EXPERIMENTAL
Intervention: Group I:E = 1:1
Number of subjects: 100

Group type: COMPARATOR
Intervention: Group I:E = 1:2
Number of subjects: 100
Study: 20628009

Group type: EXPERIMENTAL
Intervention: Opportunistic learning through frequent exposure to collinear contours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Task-specific training (bootstrap-based learning) for integrating discontinuities
Number of subjects: 0
Study: 18173844

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention consisting of 3 face-to-face and 4 telephone contacts over 6 months, focusing on increasing daily physical activity, improving dietary behaviour, and smoking cessation.
Number of subjects: 692

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 692
Study: 15135594

Group type: EXPERIMENTAL
Intervention: Immediate carotid endarterectomy (CEA)
Number of subjects: 3120

Group type: COMPARATOR
Intervention: Indefinite deferral of CEA
Number of subjects: 3120
Study: 11446848

Group type: EXPERIMENTAL
Intervention: Acetyl‐L‐carnitine 1 g twice daily for 3 months
Number of subjects: 48

Group type: COMPARATOR
Intervention: Tamoxifen 20 mg twice daily for 3 months
Number of subjects: 48
Study: 9712445

Group type: EXPERIMENTAL
Intervention: GnRHa therapy with 15 microg of diluted buserelin acetate given once a day intranasally
Number of subjects: 44

Group type: COMPARATOR
Intervention: Clomiphene citrate 50 mg daily by oral administration
Number of subjects: 44
Study: 8001518

Group type: EXPERIMENTAL
Intervention: Wheat-based RTE cereals
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oat-based RTE cereals
Number of subjects: 8

Group type: COMPARATOR
Intervention: Rice-based RTE cereal
Number of subjects: 8

Group type: COMPARATOR
Intervention: Boiled rice
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: All products
Number of subjects: 8